KATEKAT🐯 retweeted
Grateful to
1. @PhillyD covers @JNJNews's bedaquline story for his six million subscribers: youtu.be/KaVH4pvg9A0?t=255
2. @Forbes, which seems to know more about J&J's decision than they have publicly acknowledged (just release a statement, J&J! It's easy! I'll write it for you!): forbes.com/sites/willskipwor…
3. @goodgoodgood for covering this as well: goodgoodgood.co/articles/joh…
We keep fighting until bedaquiline and all other TB treatments are available to everyone everywhere--saving millions of lives and making all humans safer from the deadliest infection in human history.
KATEKAT🐯 retweeted
Holy shit...what a thing to wake up to!!
There is no power in the world quite like a year-long John Green hyper-obsession mixed with the power of Nerdfighteria.
Global Drug Facility Update on Access to Bedaquiline stoptb.org/news/global-drug-…
KATEKAT🐯 retweeted
Hey @jnjnews I DM'ed you with my number. If you need help with the press release you are hopefully writing, I'm happy to help advise on what it needs to include--a pledge that this deal will last forever, that it will not limit the quantity of bedaquiline available, and the list of countries it applies to. My services are free on this one.
KATEKAT🐯 retweeted
I love nerdfighter twitter. And now the whole world loves nerdfighter twitter. I can't quit this place as long as y'all are here. You are a terrifying and wondrous force in this world.
KATEKAT🐯 retweeted
I keep crying out of nowhere. What a good day to support @MSF, @PIH, and all the global health orgs and activists who've been fighting for tuberculosis treatment access for decades. These people are my heroes, and today I'll be making donations in honor of TB survivors around the world.
PIH: pih.org/?form=donate
MSF: msf.org/donate
KATEKAT🐯 retweeted
!!!!!!!!!!!!! @JNJNews, THANK YOU for choosing #PatientsNotPatents. Takes real guts to live up to your credo. Generic bedaquiline WILL BE AVAILABLE in almost every country with a high tuberculosis burden. I am so happy and grateful to the Stop TB Partnership, J&J, and especially the activists around the world who are standing up for TB patients. So much more work to do, but WHAT WONDERFUL NEWS TO WAKE UP TO.
Global Drug Facility Update on Access to Bedaquiline stoptb.org/news/global-drug-…
KATEKAT🐯 retweeted
I want to be clear that while I think our pressure may have affected the timing, this must have been in the works for a while. The real heroes here aren't us but the Stop TB Partnership and other activists who've been working for YEARS to get to this moment. You rule. THANK YOU.
!!!!!!!!!!!!! @JNJNews, THANK YOU for choosing #PatientsNotPatents. Takes real guts to live up to your credo. Generic bedaquiline WILL BE AVAILABLE in almost every country with a high tuberculosis burden. I am so happy and grateful to the Stop TB Partnership, J&J, and especially the activists around the world who are standing up for TB patients. So much more work to do, but WHAT WONDERFUL NEWS TO WAKE UP TO.
KATEKAT🐯 retweeted
this is so unbelievably disappointing. #PatientsNotPatents
It is false to suggest—as some recently have—that our patents are being used to prevent access to SIRTURO® (bedaquiline), our medicine for MDR-TB.
In fact, we have already entered into a collaboration with the Stop TB Partnership’s Global Drug Facility (“GDF”)—the largest procurer of TB medicines—which enables them to invite potential generic suppliers and purchase generic versions of SIRTURO® 100mg. On April 5, during a World Health Organization meeting, the GDF shared its intent to launch a tender for generic versions of SIRTURO® 100mg in the third quarter of 2023: social.jnj.com/3XSgjRZ
In addition, we have shipped more than 660,000 courses of SIRTURO® to 159 countries since launch. Our patents made this possible, enabling us to assist countries to scale-up their use of our medicine responsibly and sustainably and invest in multiple, critical, anti-TB efforts. For instance, in the face of rising drug resistance, we support stewardship efforts that ensure MDR-TB patients can benefit from our medicine today and in the future.
Unfortunately, the most significant barrier to treatment access for patients today is the fact that millions of patients with TB go undiagnosed every year. This is a challenge that we have invested significant resources to overcome and must all get behind if we are to achieve the global goal of ending TB.
Readers added context they thought people might want to know
J&J continue to limit a lower pricing of $1,200 for 20 months to the Global Drug Facility. Only South Africa has been granted access to this pricing outside the GDF.
Researchers suggest that Bedaquiline could still be sold at profit for as little as 25 cents per day.
msfaccess.org/jj-can-you-hea…
KATEKAT🐯 retweeted
When was the last time you saw a tweet with 830,000 views, 694 quote tweets .... and 19 likes?
It is false to suggest—as some recently have—that our patents are being used to prevent access to SIRTURO® (bedaquiline), our medicine for MDR-TB.
In fact, we have already entered into a collaboration with the Stop TB Partnership’s Global Drug Facility (“GDF”)—the largest procurer of TB medicines—which enables them to invite potential generic suppliers and purchase generic versions of SIRTURO® 100mg. On April 5, during a World Health Organization meeting, the GDF shared its intent to launch a tender for generic versions of SIRTURO® 100mg in the third quarter of 2023: social.jnj.com/3XSgjRZ
In addition, we have shipped more than 660,000 courses of SIRTURO® to 159 countries since launch. Our patents made this possible, enabling us to assist countries to scale-up their use of our medicine responsibly and sustainably and invest in multiple, critical, anti-TB efforts. For instance, in the face of rising drug resistance, we support stewardship efforts that ensure MDR-TB patients can benefit from our medicine today and in the future.
Unfortunately, the most significant barrier to treatment access for patients today is the fact that millions of patients with TB go undiagnosed every year. This is a challenge that we have invested significant resources to overcome and must all get behind if we are to achieve the global goal of ending TB.
Readers added context they thought people might want to know
J&J continue to limit a lower pricing of $1,200 for 20 months to the Global Drug Facility. Only South Africa has been granted access to this pricing outside the GDF.
Researchers suggest that Bedaquiline could still be sold at profit for as little as 25 cents per day.
msfaccess.org/jj-can-you-hea…
KATEKAT🐯 retweeted
...and that tension--I love this world and the people in it; I am disappointed by this world and the people in it--keeps me going. Thanks for being here with us. Thanks for letting me be here with you.
KATEKAT🐯 retweeted
We've got Wonder Woman on our team! Time for @JNJGlobalHealth to announce they're abandoning all secondary patents on bedaquiline so that multidrug-reistant tuberculosis patients can have affordable access to the best available medication.
You can use your voice to save millions of lives this year. Thank you @johngreen for calling attention to this issue so that we can all be superheroes. 💫💫💫
KATEKAT🐯 retweeted
Johnson & Johnson (@JNJGlobalHealth) is unjustly extending a patent on a life-saving tuberculosis drug. Today's the day for them to realize denying MDR-TB patients treatment is not worth the harm they're causing to core brands like Tylenol and Neutrogena. youtube.com/watch?v=tMhgw5SW…
KATEKAT🐯 retweeted
Tell @JNJNews their attempts to evergreen the patent on the life-saving tuberculosis drug bedaquiline is unjust and a violation of their corporate credo: secure.ethicspoint.com/domai…
And then tell the world that Johnson & Johnson is denying MILLIONS access to life-saving TB treatment.
KATEKAT🐯 retweeted
Replying to @hankgreen
You’ve got this, Hank! The entire Mythical Crew’s wishing you the best 🧡
KATEKAT🐯 retweeted
Ok, let’s do this part!!
youtu.be/x6a4hMyiwBo


















